| 3D bioprinting The goal of the establishment of Aspect Biosystems, a technology company, was to create human tissue based on demand, and many solutions have been developed to help conduct research-grade bioprocessing. In recent days, Aspect has received US$1 million support from Canadian non-profit organization Genome British Columbia. This investment from Genome BC is used to advance the company’s commercialization plan and develop its 3D bioprinting platform.  Tamer Mohamed, Aspect’s President and Chief Executive Officer, commented that 'Genome BC plays an important role in accelerating life science innovation in British Columbia and we are very pleased to receive their support'. With these additional financings, we have further enhanced our ability to meet key business needs and continue to achieve rapid growth while we work hard to create human organizations based on demand. base on needs 3D printing organization The core technology of Aspect is the Lab-on-a-Printer platform. Lab-on-a-Printer, which plays a role in laboratory chip research equipment, is essentially a 3D bio-printer driven by microfluidics. Each print head in Lab-on-a-Printer contains multiple microscopic channels for redirecting fluids or inks. This platform is a unique technology that can layer multiple cell types to create 3D structures. . An example of a Lab-on-a-Printer application is Aspect's 3DBioRing organization, which mimics the contraction and relaxation of human muscles. 'In the printing process, we can switch materials in real time,' Mohamed explained. 'We can really begin to create very complex combinations and structures that are necessary to truly reproduce what's happening in the body.' source:  △3DBioRing Muscle Tissue Platform. Photo from Aspect Biosystems Since its inception in 2013, Aspect Biosystems has undertaken a number of well-known projects within the industry, including collaboration with the Fraunhofer Institute for Toxicology and Experimental Medicine. In 2017, pharmaceutical giant Johnson & Johnson established a partnership with Aspect Biosystems and launched a project to create cartilage for knee injury. Recently, Johnson & Johnson also launched a professional 3D bioprinter at Trinity College in Dublin, Ireland. In a recent investment, Dr. Tony Brooks, CFO and Vice President of Venture and Commercialization at BC Genomics, said: 'Aspect has shown great commercial appeal in a very short period of time. We are very pleased to support their continued efforts. Growth. ' Source: Antarctic Bear 3D Printing Network |
 |
|